Taking stock of the drug industry, from the lab to the medicine chestMarch 21, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal The chief U.K. negotiator spent nearly three decades working for AstraZeneca, which advocacy groups say gives pharma too much influence. By Ed Silverman STAT+ | 8 burning questions Bernie Sanders and other senators should ask Moderna's Stéphane Bancel How exactly did you land on $130 for a Covid vaccine dose? And 7 other burning questions for Moderna CEO Stéphane Bancel. By Helen Branswell and Rachel Cohrs and Damian Garde Study finds same small rise in breast cancer risk in many forms of hormonal birth control The absolute increased risk is small for all such birth control, but the study throws into question the idea that it is lower for IUDs. By Angus Chen Adobe STAT+ | Altimmune's obesity drug fails to stand out from blockbuster treatments in early data Mid-stage trial data on Altimmune's obesity drug showed it doesn't have a leg up on other popular drugs on the market. By Allison DeAngelis Steroid drug reduces death rate in severe pneumonia, study shows The results will challenge current treatment guidelines, which advise against the use of corticosteroids in community acquired pneumonia By Matthew Herper More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments